Meanwhile, Rasgrf1 upregulation via miRNA-323-5p inhibition may ameliorate cognitive impairment by promoting synaptic plasticity, providing a potentially valuable and effective therapeutic target for cognitive dysfunction after CCH. Here, RASGRF1 is linked to columnar cell hyperplasia of the breast.